Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics Inc. (LSTA) is a clinical-stage biopharmaceutical company pioneering novel peptide-based therapies for advanced solid tumors. This dedicated news hub provides investors and researchers with essential updates on the company's progress in enhancing cancer treatment through innovative drug delivery systems.
Access timely reports on clinical trial developments, strategic research partnerships, and regulatory milestones related to Lisata's lead candidate certepetide and its CendR Platform technology. Our curated collection includes press releases on trial initiations, scientific presentations, and corporate announcements that demonstrate the company's evolving role in oncology therapeutics.
Key updates cover advancements in pancreatic cancer research, glioblastoma treatment studies, and collaborative projects with academic institutions. The resource serves as a centralized reference for tracking how Lisata's tumor-penetrating peptide technology may improve existing cancer treatment paradigms through enhanced drug delivery mechanisms.
Bookmark this page for structured access to verified information about Lisata's clinical programs and corporate developments. Check regularly for new insights into the company's efforts to address unmet needs in solid tumor oncology through targeted therapeutic strategies.
Lisata Therapeutics (Nasdaq: LSTA) reported Q3 2025 results and a business update on Nov 6, 2025. The company reported $19.0 million in cash and expects that available funds will fund operations into the first quarter of 2027. Operating expenses for Q3 were $4.4 million with a net loss of $4.2 million versus $4.9 million a year earlier.
Clinical progress: positive preliminary and pooled data from ASCEND (including four complete responses in treated patients), corroborative data from iLSTA, and encouraging surgical and survival signals from CENDIFOX (50% R0 resection, 70% pathologic partial response, 60% two-year OS in the PDAC subset). Business deals include a global nonexclusive license with Catalent to evaluate certepetide in ADCs and a strategic alliance with GATC Health for AI-driven discovery.
Lisata Therapeutics (Nasdaq: LSTA) won Overall BioPharma Solution of the Year at the 2025 BioTech Breakthrough Awards on Nov 6, 2025, marking its second consecutive year receiving a BioTech Breakthrough Award.
Lisata is a clinical-stage company using its CendR Platform® to enhance tumor-targeted, tissue-penetrating delivery of anti-cancer therapies. Recent clinical highlights include ASCEND Phase 2b high-dose results showing 6‑month PFS 60.8% vs 25% placebo and ORR 45.2% vs 19% placebo, and the iLSTA trial reporting 60% ORR and 100% disease control rate in locally advanced, non-resectable pancreatic cancer, including a complete response.
Lisata Therapeutics (Nasdaq: LSTA) highlighted positive preclinical results on November 4, 2025 after Catalent presented data at the 16th Annual World ADC San Diego Conference (Nov 3–6, 2025).
Catalent reported that incorporating Lisata’s proprietary iRGD cyclic peptide certepetide as a non-cytotoxic payload in its SMARTag® ADC platform improved tumor-selective penetration and broadened intratumoral distribution of cytotoxic payloads, and also enhanced ADC efficacy in preclinical models. Lisata emphasized this finding as supportive of its licensing partnership with Catalent and its strategy to use certepetide to boost therapeutic delivery across modalities.
Lisata Therapeutics (Nasdaq: LSTA) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 6, 2025 after market close.
The company will host a conference call at 4:30 p.m. Eastern time the same day. Participants are encouraged to dial in 10 minutes early. Dial-in numbers: toll-free (800) 715-9871, toll/intl (646) 307-1963 with Conference ID 6375221. A live webcast will be available under the Investors & News section of Lisata’s website, with a replay posted two hours after the call and accessible for 12 months.
Lisata Therapeutics (NASDAQ:LSTA) will present a corporate overview at LD Micro Main Event XIX in San Diego, California, taking place October 19–21, 2025. David J. Mazzo, Ph.D., President and CEO, is scheduled to present on Monday, October 20 at 10:30 a.m. PT. One-on-one investor meetings will be held throughout the conference. The presentation will be available for online viewing and interested parties can request meeting information or schedule a one-on-one by emailing jmenditto@lisata.com.
Lisata Therapeutics (Nasdaq: LSTA) and Catalent announced on October 8, 2025 a global, non-exclusive license allowing Catalent to incorporate Lisata’s certepetide and analogs into ADCs developed with Catalent’s SMARTag® platform.
Catalent gains worldwide rights to evaluate certepetide as SMARTag® payloads across multiple ADCs and may partner third parties. Lisata is eligible for over $10 million in tiered study-initiation milestone payments plus revenue sharing on future sales and partnerships. Catalent’s preclinical data provide proof-of-concept that iRGD peptides can improve ADC efficacy and pharmacokinetics; related preclinical work will be highlighted at the November World ADC conference in San Diego.
Lisata Therapeutics (Nasdaq: LSTA) reported encouraging preliminary results from the pancreatic cancer (PDAC) cohort of its Phase 1/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies. The trial, led by Dr. Anup Kasi at KU Cancer Center, showed promising outcomes in treating resectable and borderline resectable PDAC.
Key findings from the 35-patient PDAC cohort include: 50% R0 resection rate and 70% pathologic partial response among the 10 patients who completed pre-surgical therapy. The study demonstrated a 60% two-year overall survival rate and 12-month median disease-free survival. Importantly, the combination therapy showed enhanced immune cell infiltration and increased expression of immune markers, suggesting potential transformation of pancreatic tumors from "immune-cold" to "immune-hot."
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's President and CEO, David J. Mazzo, Ph.D., will deliver a pre-recorded corporate overview presentation, which will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. The conference is scheduled to take place in New York City from September 8-10, 2025.
Lisata Therapeutics (NASDAQ:LSTA) reported Q2 2025 financial results and provided updates on its clinical development portfolio. The company's lead candidate certepetide showed positive preliminary results in multiple clinical trials for advanced solid tumors. Key financial metrics include $22.0 million in cash and equivalents, with runway extending into Q4 2026.
Notable developments include positive preliminary data from the ASCEND trial for pancreatic cancer and the iLSTA trial. The company reported Q2 2025 revenue of $70,000 and reduced operating expenses to $4.9 million, down 10.6% year-over-year. A new USPTO patent extends certepetide's protection until March 2040.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, will release its Q2 2025 financial results on Thursday, August 7, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register to receive dial-in details and are encouraged to join 15 minutes before the start time. A live webcast will be available on Lisata's website, with a 12-month replay option.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
